PMID- 35119219
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230916
IS  - 2578-5745 (Electronic)
IS  - 2578-5745 (Linking)
VI  - 4
IP  - 5
DP  - 2022 May
TI  - Journal Club Review of "Comparison of Two Rituximab Induction Regimens for 
      Antineutrophil Cytoplasm Antibody-Associated Vasculitis: Systematic Review and 
      Meta-Analysis".
PG  - 406-409
LID - 10.1002/acr2.11409 [doi]
AB  - OBJECTIVE: The objective of this study was to compare the efficacy and safety of 
      two rituximab (RTX) regimens for the induction of remission in severe 
      antineutrophil cytoplasm antibody-associated vasculitis (AAV): the four-dose (375 
      mg/m(2) intravenously weekly) versus the two-dose (1000 mg intravenously 
      biweekly) regimen. METHODS: A systematic review was performed to identify studies 
      using the four- and/or two-dose RTX regimens for induction of remission in severe 
      AAV. Disease status 6 months after RTX infusion was required for inclusion. 
      Patients were excluded if they received concomitant cyclophosphamide or plasma 
      exchange. The primary end point was the proportion of patients in complete 
      remission at 6 months. The pooled estimate was obtained by using meta-analysis 
      methods for proportions with random effects. Secondary end points included 
      antineutrophil cytoplasm antibody status, number of patients with B-cell 
      depletion, mean prednisone dose, infections, and death. RESULTS: A total of 27 
      studies and 506 patients were included for analysis: 361 patients received the 
      four-dose regimen, and 145 patients received the two-dose regimen. Most patients 
      had relapsing disease at inclusion (83% and 92% of patients, respectively). There 
      was no significant difference between the four- and two-dose regimens, with a 
      complete remission achieved in 85% (95% confidence interval [CI]: 70-96) and 91% 
      (95% CI: 79-99) of patients, respectively. At 6 months, both regimens were 
      associated with a similar mean daily prednisone dose (8.1 mg), infections (12% in 
      both), and death (1% vs. 0%, respectively). CONCLUSION: No difference was found 
      in terms of efficacy or safety between the four- and two-dose RTX regimens for 
      induction of remission in severe AAV. 
      https://onlinelibrary.wiley.com/doi/10.1002/acr2.11274 Benard V, Farhat C, 
      Zarandi-Nowroozi M, Durand M, Charles P, Puechal X, et al. Comparison of two 
      rituximab induction regimens for antineutrophil cytoplasm antibody-associated 
      vasculitis: systematic review and meta-analysis. ACR Open Rheumatol 
      2021;3:484-94.
CI  - (c) 2022 The Author. ACR Open Rheumatology published by Wiley Periodicals LLC on 
      behalf of American College of Rheumatology.
FAU - Elfishawi, Mohanad
AU  - Elfishawi M
AUID- ORCID: 0000-0002-4795-8991
AD  - Mohanad Elfishawi, MBBCh, MS: Mayo Clinic College of Medicine and Science, 
      Rochester, Minnesota.
LA  - eng
PT  - News
DEP - 20220204
PL  - United States
TA  - ACR Open Rheumatol
JT  - ACR open rheumatology
JID - 101740025
PMC - PMC9096519
EDAT- 2022/02/05 06:00
MHDA- 2022/02/05 06:01
PMCR- 2022/02/04
CRDT- 2022/02/04 08:43
PHST- 2021/10/15 00:00 [received]
PHST- 2021/12/10 00:00 [accepted]
PHST- 2022/02/05 06:00 [pubmed]
PHST- 2022/02/05 06:01 [medline]
PHST- 2022/02/04 08:43 [entrez]
PHST- 2022/02/04 00:00 [pmc-release]
AID - ACR211409 [pii]
AID - 10.1002/acr2.11409 [doi]
PST - ppublish
SO  - ACR Open Rheumatol. 2022 May;4(5):406-409. doi: 10.1002/acr2.11409. Epub 2022 Feb 
      4.